Related Experiment Video
Updated: May 15, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice
Zuzana Tothova1, David P Steensma, Benjamin L Ebert
1Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA.
Abstract:
An increasingly complete compendium of recurrently mutated genes in myelodysplastic syndromes (MDS) has been defined, and the application of massively parallel sequencing to identify mutations in clinical practice now promises to improve the care of patients with this disease. More than 25 recurrent MDS-associated somatic mutations have been identified, involving biologic pathways as diverse as chromatin remodeling and pre-mRNA splicing. Several of these mutations have been shown to have prognostic implications that are independent of existing risk stratification systems based on clinical and pathologic parameters. Application of these recent discoveries to diagnosis, prognosis, risk stratification, and treatment selection for patients with MDS has the potential to improve patient outcomes. Here, we review recent advances in MDS and discuss potential applications of these discoveries to clinical practice.
Insights
Discoveries in myelodysplastic syndromes (MDS) reveal over 25 recurrent mutations impacting patient care. These genetic insights offer improved diagnosis, prognosis, and treatment selection for MDS patients.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Understanding the genetic landscape of MDS is crucial for improving patient outcomes.
- Recurrently mutated genes play a significant role in MDS pathogenesis.
Purpose of the Study:
- To review recent advances in the genetic understanding of myelodysplastic syndromes (MDS).
- To discuss the clinical applications of identified MDS-associated mutations.
- To highlight the potential of genetic discoveries to improve patient care in MDS.
Main Methods:
- Comprehensive review of identified recurrently mutated genes in myelodysplastic syndromes (MDS).
- Analysis of biologic pathways involved in MDS pathogenesis, including chromatin remodeling and pre-mRNA splicing.
- Evaluation of the prognostic implications of specific MDS mutations.
Main Results:
- Over 25 recurrent MDS-associated somatic mutations have been identified.
- These mutations involve diverse biological pathways critical to MDS.
- Several mutations demonstrate prognostic value independent of existing clinical and pathological risk stratification.
Conclusions:
- Genetic discoveries in MDS have significantly advanced our understanding of the disease.
- Application of these findings to diagnosis, prognosis, and treatment selection holds promise for improved patient outcomes.
- Continued research into MDS genetics is essential for further clinical practice improvements.
